First line treatment for unresectable stage III or IV cutaneous melanoma (according to AJCC version 8) with anti-PD1 monotherapy (nivolumab or pembrolizumab) or anti-PD1 + anti-CTL4A combination therapy (nivolumab and ipilimumab).
Anticipated life expectancy exceeding 3 months.
Aged 18 years or older and able to provide written informed consent.
Patients who have completed adjuvant treatment with anti-PD1 immunotherapy at least 6 months ago can be included.
You may not be if
Prior treatment for irresectable stage III or stage IV melanoma with BRAF/MEK inhibitors.
Presence of progressive/symptomatic brain metastases at baseline.
WHO performance score ≥ 2.
Adjuvant treatment with anti-PD1 immunotherapy received within the last 6 months.
Patients undergoing experimental treatments or therapies.
Presence of any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study.
Unwillingness or inability to comply with study and follow-up procedures.
Clareo Health | Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
